U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H34O6
Molecular Weight 430.5339
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXBUDESONIDE

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@H](CCC)O2)C(=O)CO

InChI

InChIKey=VOVIALXJUBGFJZ-VXKMTNQYSA-N
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21+,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H34O6
Molecular Weight 430.5339
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Dexbudesonide (22R- Budesonide) is an epimer R of Budesonide, last is used as a mixture of 22R and 22S epimers for the topical treatment of asthma, rhinitis, and inflammatory bowel disease

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Skin reactions to inhaled corticosteroids.
2001
Topical corticosteroids in nasal polyposis.
2001
Ultrasonic nebulization system for respiratory drug delivery.
2001
Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
2001 Apr
Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma.
2001 Apr
Glucocorticoids and TGF-beta1 synergize in augmenting fibroblast mediated contraction of collagen gels.
2001 Apr
A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects.
2001 Apr
Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up.
2001 Apr
beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide.
2001 Apr
Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years.
2001 Apr
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
2001 Apr
Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home.
2001 Feb
Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.
2001 Feb
Comparison of handling and acceptability of two spacer devices in young children with asthma.
2001 Feb
Generalized eczematous reaction to budesonide in a nasal spray with cross-reactivity to triamcinolone.
2001 Feb
The use of budesonide in the treatment of active Crohn's disease is good clinical practice.
2001 Feb
Budesonide: is no evidence of a difference the same as evidence of no difference?
2001 Feb
A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis.
2001 Feb
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
2001 Feb
Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity.
2001 Feb 1
Asthma, corticosteroids, and growth.
2001 Feb 22
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases].
2001 Jan
Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial.
2001 Jan
Pneumomediastinum and pneumopericardium: unusual and rare complications of asthma in a 4 years old girl.
2001 Jan-Feb
Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma.
2001 Jan-Feb
Corticosteroids in the treatment of pediatric allergic rhinitis.
2001 Jul
Assessing the effect of intranasal steroids on growth.
2001 Jul
Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children.
2001 Jul
Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids.
2001 Jun
Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study.
2001 Jun
A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease.
2001 Jun
Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease.
2001 Jun
Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism.
2001 Jun
Relevance and reproducibility of patch-test reactions to corticosteroids.
2001 Jun
On-demand relief treatment for asthma.
2001 Jun 9
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Nebulised epinephrine or corticosteroids in croup.
2001 Mar
[Solid combination of budesonide and formoterol in the treatment of bronchial asthma].
2001 Mar
The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children.
2001 Mar
Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma.
2001 Mar
The risk of cataract among users of inhaled steroids.
2001 Mar
Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects.
2001 Mar
Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells.
2001 May
Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease.
2001 May
A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma.
2001 May
Patch test results with tixocortol pivalate and budesonide in Germany and Austria.
2001 May
Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice.
2001 May
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal.
2001 May
Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.
2001 May
[Precise direction or flexible self-control. How strictly must the asthma patient adhere to medical advice?].
2001 May 10
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In vitro biotransformation of the 22R (Dexbudesonide) and 22S epimers of the topical steroid budesonide was studied in the S-9 fraction of human liver, bronchus, skin and colonic mucosa. A marked decay of the initial concentration of unchanged budesonide epimers was noticed after 2 h incubation in cultured human hepatocytes, while only a small decrease was observed after 24 h incubation in cultured human airway smooth muscle cells and BEAS-2B cells. The 22R epimer of budesonide suffered greater in vitro biotransformation than the 22S epimer in human hepatic, bronchial and colonic tissues.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:24:16 UTC 2023
Edited
by admin
on Wed Jul 05 23:24:16 UTC 2023
Record UNII
2HI1006KPH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXBUDESONIDE
INN   WHO-DD  
INN  
Official Name English
dexbudesonide [INN]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 16,17-BUTYLIDENEBIS(OXY)-11,21-DIHYDROXY-, (11.BETA.16.ALPHA.(R))
Common Name English
Dexbudesonide [WHO-DD]
Common Name English
(R)-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE 16,17-ACETAL WITH BUTYRALDEHYDE
Common Name English
R-BUDESONIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID40101779
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
CAS
51372-29-3
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
ECHA (EC/EINECS)
257-161-7
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
SMS_ID
100000087782
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
INN
7805
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
EVMPD
SUB01627MIG
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
ChEMBL
CHEMBL2110662
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
WIKIPEDIA
Dexbudesonide
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
NCI_THESAURUS
C80814
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
PUBCHEM
40000
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
FDA UNII
2HI1006KPH
Created by admin on Wed Jul 05 23:24:17 UTC 2023 , Edited by admin on Wed Jul 05 23:24:17 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY